OWC Pharmaceutical Research Corp (OWCP)

[Triple9]

Multiple revenue streams are going to be disclosed in Q2 and Q3 IMHO.

First, we have the 3 consulting contacts that were signed with US States. We know OWC was in the US and Canada recently, so perhaps there are more than 3 contracts by now.

International Consultancy
• Covering expertise with growers, breeds,
patients treatments, educational
programs, regulation and more.
• Signed 3 agreements to consult in the US.

On Page 11 http://www.owcpharma.com/wp-content/uploads/2017/01/OWC-PPT-1-2017-FINAL.pdf

Second, topical skin cremes. As soon as IRB approval is granted for safety and efficacy, cremes for psoriasis and other skin conditions will hit the markets.

Psoriasis (Skin Disease)
• Pharma-grade ‘challenge tests’ successfully completed
05/2016
• Safety study at Sheba, Tel Hashomer under approved
IRB (Helsinki) protocol. To be completed 3/2017
• In-vitro psoriasis efficacy study of the topical crème to
be completed by 3/2017
• IP owned by OWCP
• EXPECTED MARKET READINESS : Q2/2017

On page 14 of 2017 PPT

Third, licensing of two delivery systems- sublingual tablet and topical creme.

Cannabis Based Products
IP-owned developed of new innovative and tested delivery
systems.
• Two products ready to market:
• Sublingual Soluble tablet: replacement of smoking, pain
treatment. more than 10 million potential patients in the approved
MMJ states.
• Topical crème: Treatment for different skin diseases starting with
tested psoriasis. ~8 Million Psoriasis patients US & Canada (2.5% of
population), 3 years potential is 2-4 millions monthly income
(following current market prices)
• Fixed and controlled dosage
• Quality controlled
• Waiting for safety and clinical results

On page 10 of the 2017 PPT

The interesting thing for PPS for OWCP is that BioTech and Pharma companies have very different PE ratios. That's because Pharma cos have a limited exclusivity, 7-12 years generally, for drugs while technology patents such as OWCP's cannabis delivery systems should have 20+ years of patent protection. NYU Stern business school did a recent survey of 426 BioTech companies and found an average PE ratio of 321. Same study of 164 Pharma companies found average PE ratio of 182. Big difference!

http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/pedata.html

It's beyond me to model the PPS for OWCP in Q2-Q3. I'll wait for the professionals. However, my gut tells me we will be in the multi dollar range easily.